Qitao Yu

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

Yunpeng Yang, Zhehai Wang, Jian Fang et al. · Journal of Thoracic Oncology · 2020 · 396 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study

Yunpeng Yang, Jiya Sun, Zhehai Wang et al. · Journal of Thoracic Oncology · 2021 · 148 citations · Full text

Medicine, Oncology, Pharmacology +17

[Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients].

Jinwan Wang, Yan Sun, Qitao Yu et al. · PubMed · 2005 · 147 citations

Medicine, Oncology, Pharmacology +13

Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study

Yuankai Shi, Xingsheng Hu, Shucai Zhang et al. · The Lancet Respiratory Medicine · 2021 · 121 citations

Medicine, Molecular Genetics, Oncology +17

c-Myc-activated long non-coding RNA H19 downregulates miR-107 and promotes cell cycle progression of non-small cell lung cancer.

Jiandong Cui, Juanmei Mo, Min Luo et al. · PubMed · 2015 · 103 citations

Medicine, Molecular Biology, Oncology +17